Medical Examination and Clinical Diagnosis

Study on diffuse cystic lung disease based on deep learning

  • Jia XIANG ,
  • Qiantong CHEN ,
  • Yingxin LU ,
  • Sijie ZHENG ,
  • Junjie HUANG ,
  • Yingying CHEN ,
  • Suidan HUANG ,
  • Huai. CHEN
Expand
  • *.Department of Radiology,the Second Affiliated Hospital of Guangzhou Medical University,Guangzhou 510260,Guangdong,China
    *.Guangzhou Medical University,Guangzhou 510182,Guangdong,China

Received date: 2024-04-07

  Online published: 2024-10-22

Abstract

Objective To develop deep learning-based auxiliary diagnostic models for diverse pulmonary diffuse cystic diseases, and subsequently evaluate their classification performance to identify the optimal model for clinical diagnosis. Methods A total of 288 patients diagnosed with idiopathic pulmonary fibrosis (IPF), pulmonary lymphangioleiomyomatosis (PLAM), and pulmonary Langerhans cell histiocytosis (PLCH) were prospectively enrolled from the First Affiliated Hospital of Guangzhou Medical University between January 2010 and October 2022, comprising 76 cases of IPF, 179 cases of PLAM, and 33 cases of PLCH.A total of 877 CT cases were collected, comprising 232 cases of IPF, 557 cases of PLAM, and 88 cases of pulmonary PLCH. Based on the cutoff date of December 31, 2019, the CT scans were divided into two datasets: dataset A consisted of 500 CT scans including 185 IPF cases, 265 PLAM cases, and 50 PLCH cases; while dataset B comprised 377 CT scans with a distribution of 47 IPFcases, 292 PLAMcases, and 38 PLCH cases. The Dataset A was randomly partitioned into training set, validation set, and test set in a ratio of 7∶1∶2. Subsequently, six distinct deep learning neural networks were employed for training after preprocessing and data augmentation. Receiver operating characteristic curves were generated to assess the model performance using metrics such as area under the curve (AUC), accuracy, sensitivity, specificity, and F1 score in order to identify the optimal model. Furthermore, a test set B comprising 30 randomly selected cases from dataset B for each disease type was utilized to evaluate the trained optimal model by employing the same aforementioned metrics. Results In test A, six well-established diagnostic models demonstrated superior classification performance for IPF and LAM, with an AUC greater than 0.9. For LCH, EfficientNet exhibited low classification efficiency with an AUC between 0.6 and 0.7, while Vgg11 showed an AUC between 0.8 and 0.9; the other four models displayed excellent classification efficiency with an AUC greater than 0.9. Except for Inception V3, the remaining five diagnostic models performed poorly in identifying and classifying LCH lesions. Considering multiple indicators, the InceptionV3 model showcased optimal comprehensive performance among the six models, achieving high evaluation parameters such as overall accuracy (94.90%), precision (93.49%), recall (90.84%), and specificity (96.91%). TestB was conducted using the trained InceptionV3 model resulting in an accuracy of 81%, precision of 82%, recall of 81%, and specificity of 90%. Conclusions Six recognition and classification models, developed using deep learning technology in conjunction with pulmonary CT images, demonstrate effective discrimination between LAM, LCH, and IPF. Notably, the model constructed utilizing the InceptionV3 neural network exhibits superior efficiency in accurately recognizing and classifying IPF and LAM.

Cite this article

Jia XIANG , Qiantong CHEN , Yingxin LU , Sijie ZHENG , Junjie HUANG , Yingying CHEN , Suidan HUANG , Huai. CHEN . Study on diffuse cystic lung disease based on deep learning[J]. The Journal of Practical Medicine, 2024 , 40(19) : 2747 -2754 . DOI: 10.3969/j.issn.1006-5725.2024.19.014

References

1 BALDI B G, CARVALHO C R R, DIAS O M, et al. Diffuse cystic lung diseases: differential diagnosis [J]. J Bras Pneumol, 2017, 43(2): 140-149. doi:10.1590/s1806-37562016000000341
2 KOSLOW M, LYNCH D A, COOL C D, et al. Lymphangioleiomyomatosis and Other Cystic Lung Diseases [J]. Immunol Allergy Clin North Am, 2023, 43(2): 359-377. doi:10.1016/j.iac.2023.01.003
3 OBAIDAT B, YAZDANI D, WIKENHEISER-BROKAMP K A, et al. Diffuse cystic lung diseases [J]. Respir Care, 2020, 65(1): 111-126. doi:10.4187/respcare.07117
4 REFAEE T, SALAHUDDIN Z, FRIX A N, et al. Diagnosis of idiopathic pulmonary fibrosis in high-resolution computed tomography scans using a combination of handcrafted radiomics and deep learning [J]. Front Med (Lausanne), 2022, 9: 915243. doi:10.3389/fmed.2022.915243
5 JONAS A, MUELLY M, GUPTA N, et al. Machine learning to distinguish lymphangioleiomyomatosis from other diffuse cystic lung diseases [J]. Respir Investig, 2022, 60(3): 430-433. doi:10.1016/j.resinv.2022.01.001
6 RAGHU G, REMY-JARDIN M, RICHELDI L, et al. Idiopathic pulmonary fibrosis (an Update) and progressive pulmonary fibrosis in adults: An official ATS/ERS/JRS/ALAT clinical practice guideline [J]. Am J Respir Crit Care Med, 2022, 205(9): e18-e47.
7 GUPTA N, FINLAY G A, KOTLOFF R M, et al. Lymphangioleiomyomatosis diagnosis and management: high-resolution chest computed tomography, transbronchial lung biopsy, and pleural disease management. An official american thoracic society/japanese respiratory society clinical practice guideline [J]. Am J Respir Crit Care Med, 2017,196(10):1337-1348.
8 GOYAL G, TAZI A, GO R S, et al. International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults [J]. Blood, 2022, 139(17): 2601-2621. doi:10.1182/blood.2021014343
9 YU W, ZHOU H, GOLDIN J G, et al. End-to-end domain knowledge-assisted automatic diagnosis of idiopathic pulmonary fibrosis (IPF) using computed tomography (CT) [J]. Med Phys, 2021, 48(5): 2458-2467. doi:10.1002/mp.14754
10 DUQUENNE J B, DUYSINX B, RADERMECKER M, et al. Cystic lung diseases [J]. Rev Mal Respir, 2021, 38(3): 257-268. doi:10.1016/j.rmr.2021.01.016
11 RADZIKOWSKA E. Update on pulmonary langerhans cell histiocytosis [J]. Front Med (Lausanne), 2020, 7: 582581. doi:10.3389/fmed.2020.582581
12 佘巍巍,王昌明,曾锦荣,等. 国内20年肺淋巴管肌瘤病的误诊原因汇总分析[J]. 实用医学杂志,2010,26(22):4157-4158.
13 XU W, CUI H, LIU H, et al. The value of transbronchial lung biopsy in the diagnosis of lymphangioleiomyomatosis [J]. BMC Pulm Med, 2021, 21(1): 146. doi:10.1186/s12890-021-01518-2
14 TORRE O, HARARI S. The diagnosis of cystic lung diseases: A role for bronchoalveolar lavage and transbronchial biopsy? [J]. Respir Med, 2010, 104 : S81-S85. doi:10.1016/j.rmed.2010.03.021
15 LORILLON G, TAZI A. How I manage pulmonary Langerhans cell histiocytosis [J]. Eur Respir Rev, 2017, 26(145): 170070. doi:10.1183/16000617.0070-2017
16 RADZIKOWSKA E, B?ASI?SKA-PRZERWA K, WIATR E, et al. Pneumothorax in patients with pulmonary langerhans cell histiocytosis [J]. Lung, 2018, 196(6): 715-720. doi:10.1007/s00408-018-0155-1
17 VAN CLEEMPUT J, SONAGLIONI A, WUYTS W A, et al. Idiopathic pulmonary fibrosis for cardiologists: differential diagnosis, cardiovascular comorbidities, and patient management [J]. Adv Ther, 2019, 36(2): 298-317. doi:10.1007/s12325-018-0857-z
18 GHANG B, NAM S H, LEE J, et al. Risk of progression of idiopathic pulmonary fibrosis to connective tissue disease: a long-term observational study in 527 patients [J]. Clin Rheumatol, 2021, 40(6): 2447-256. doi:10.1007/s10067-021-05659-x
19 PODOLANCZUK A J, THOMSON C C, REMY-JARDIN M, et al. Idiopathic pulmonary fibrosis: state of the art for 2023 [J]. Eur Respir J, 2023, 61(4): 2200957. doi:10.1183/13993003.00957-2022
20 车思雨,蒋依宁,韩广庆,等. 基于CT图像的神经网络模型鉴别纯磨玻璃样微浸润性腺癌和浸润性腺癌[J]. 实用医学杂志,2020,36(23):3273-3278. doi:10.3969/j.issn.1006-5725.2020.23.022
21 郭润财,王蕾,黄振国,等. 基于从头训练模式深度学习卷积神经网络模型评估急性肺栓塞的价值[J]. 实用医学杂志,2023,39(22):2979-2983. doi:10.3969/j.issn.1006-5725.2023.22.021
22 LEE J, LIU C, KIM J, et al. Deep learning for rare disease: A scoping review [J]. J Biomed Inform, 2022, 135: 104227. doi:10.1016/j.jbi.2022.104227
23 WALSH S L F, CALANDRIELLO L, SILVA M, et al. Deep learning for classifying fibrotic lung disease on high-resolution computed tomography: a case-cohort study [J]. Lancet Respir Med, 2018, 6(11): 837-845. doi:10.1016/s2213-2600(18)30286-8
24 BRATT A, WILLIAMS J M, LIU G, et al. Predicting usual interstitial pneumonia histopathology from chest CT imaging with deep learning [J]. Chest, 2022, 162(4): 815-823. doi:10.1016/j.chest.2022.03.044
25 MADDALI M V, KALRA A, MUELLY M, et al. Development and validation of a CT-based deep learning algorithm to augment non-invasive diagnosis of idiopathic pulmonary fibrosis [J]. Respir Med, 2023, 219: 107428. doi:10.1016/j.rmed.2023.107428
26 HUANG X, SI W, YE X, et al. Novel 3D-based deep learning for classification of acute exacerbation of idiopathic pulmonary fibrosis using high-resolution CT [J]. BMJ Open Respir Res, 2024, 11(1): e002226. doi:10.1136/bmjresp-2023-002226
27 THILLAI M, OLDHAM J M, RUGGIERO A, et al. Deep learning-based segmentation of CT scans predicts disease progression and mortality in IPF [J]. Am J Respir Crit Care Med, 2024,210(4):465-472. doi:10.1164/rccm.202311-2185oc
Outlines

/